On Jun. 2, 2021, RELIEF THERAPEUTICS reported that its collaboration partner, NRx Pharmaceuticals, announced that it had submitted an application to the U.S. Food and Drug Administration (FDA) seeking Emergency Use Authorization (EUA) for the use of aviptadil in the treatment of critical COVID-19 in patients with respiratory failure.